FDA notified healthcare professionals and patients that companies that
> manufacture and distribute pergolide have agreed to withdraw the drug
> from the market. Pergolide is a dopamine agonist (DA) used with
> levodopa and carbidopa to manage the signs and symptoms of Parkinson’s
> disease. Results of two new studies showed that some patients with
> Parkinson’s disease treated with pergolide had serious damage to their
> heart valves when compared to patients who did not receive the drug.
> These two studies confirm earlier studies that also described this
> problem. Patients currently taking pergolide should contact their
> healthcare professional about alternate treatments and not abruptly stop
> taking their medication. Healthcare professions should assess their
> patient’s need for DA therapy. If continued treatment with a DA is
> needed, another DA should be substituted for pergolide.
>
> Read the complete MedWatch 2007 Safety summary, including a link to the
> FDA Public Health Advisory regarding this issue at:
> http://www.fda.gov/medwatch/safety/2007/safety07.htm#Pergolide” target=”_blank”>http://www.fda.gov/medwatch/safety/2007/safety07.htm#Pergolide
The Legal Examiner and our Affiliate Network strive to be the place you look to for news, context, and more, wherever your life intersects with the law.
Comments for this article are closed.